| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Hypersensitivity | 11 | 2020 | 401 | 4.41 | Why? |
| Penicillins | 7 | 2019 | 132 | 2.06 | Why? |
| Skin Tests | 7 | 2019 | 229 | 1.65 | Why? |
| Anti-Bacterial Agents | 10 | 2020 | 10083 | 1.20 | Why? |
| Dapsone | 1 | 2018 | 59 | 0.72 | Why? |
| Drug Labeling | 1 | 2018 | 65 | 0.72 | Why? |
| Azacitidine | 1 | 2017 | 42 | 0.68 | Why? |
| beta-Lactams | 1 | 2019 | 210 | 0.66 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2017 | 99 | 0.63 | Why? |
| Drug Eruptions | 2 | 2018 | 319 | 0.62 | Why? |
| Interleukin-6 | 4 | 2021 | 7522 | 0.56 | Why? |
| Allergens | 2 | 2018 | 728 | 0.55 | Why? |
| Myelodysplastic Syndromes | 1 | 2017 | 261 | 0.53 | Why? |
| Pneumonia, Pneumocystis | 1 | 2018 | 322 | 0.52 | Why? |
| Anaphylaxis | 3 | 2020 | 940 | 0.52 | Why? |
| Coxiella burnetii | 1 | 2012 | 120 | 0.46 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.45 | Why? |
| Staphylococcal Infections | 1 | 2021 | 1099 | 0.44 | Why? |
| Bacterial Vaccines | 1 | 2012 | 139 | 0.44 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.44 | Why? |
| Q Fever | 1 | 2012 | 130 | 0.43 | Why? |
| Sulfonamides | 1 | 2019 | 1294 | 0.41 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2017 | 676 | 0.40 | Why? |
| Bacteremia | 1 | 2021 | 1372 | 0.40 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.39 | Why? |
| Australia | 8 | 2021 | 6306 | 0.39 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.38 | Why? |
| Antimicrobial Stewardship | 1 | 2017 | 931 | 0.37 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2019 | 170 | 0.35 | Why? |
| Hypersensitivity, Delayed | 2 | 2018 | 81 | 0.35 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.34 | Why? |
| Endocarditis, Bacterial | 1 | 2012 | 344 | 0.34 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.32 | Why? |
| Anti-Infective Agents | 1 | 2018 | 1766 | 0.32 | Why? |
| Cross Reactions | 1 | 2017 | 4374 | 0.30 | Why? |
| Immunocompromised Host | 2 | 2019 | 5150 | 0.30 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.28 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 2426 | 0.27 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.27 | Why? |
| Adverse Drug Reaction Reporting Systems | 2 | 2020 | 694 | 0.27 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.25 | Why? |
| Zinc | 2 | 2021 | 817 | 0.25 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.25 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.24 | Why? |
| T-Lymphocytes | 1 | 2018 | 6670 | 0.21 | Why? |
| Epiglottitis | 1 | 2018 | 25 | 0.19 | Why? |
| Bacterial Capsules | 1 | 2018 | 39 | 0.19 | Why? |
| Buruli Ulcer | 1 | 2018 | 17 | 0.18 | Why? |
| Mycobacterium ulcerans | 1 | 2018 | 15 | 0.18 | Why? |
| Haemophilus Vaccines | 1 | 2018 | 76 | 0.18 | Why? |
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 279 | 0.18 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.18 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.18 | Why? |
| Drug Hypersensitivity Syndrome | 1 | 2019 | 74 | 0.17 | Why? |
| Anemia, Hemolytic | 1 | 2018 | 70 | 0.17 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 66 | 0.17 | Why? |
| Interleukin-1 | 1 | 2021 | 438 | 0.17 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.17 | Why? |
| HLA-A Antigens | 1 | 2019 | 196 | 0.17 | Why? |
| Drug Resistance, Microbial | 2 | 2018 | 419 | 0.17 | Why? |
| Immunocompetence | 1 | 2018 | 280 | 0.16 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2017 | 325 | 0.16 | Why? |
| Male | 25 | 2021 | 367725 | 0.16 | Why? |
| Neisseria meningitidis | 1 | 2018 | 229 | 0.16 | Why? |
| Humans | 39 | 2021 | 930598 | 0.16 | Why? |
| Female | 26 | 2021 | 380317 | 0.16 | Why? |
| Pneumocystis carinii | 1 | 2018 | 205 | 0.15 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.15 | Why? |
| Immunodominant Epitopes | 1 | 2021 | 813 | 0.15 | Why? |
| Inpatients | 3 | 2021 | 5161 | 0.15 | Why? |
| Vancomycin | 1 | 2019 | 328 | 0.15 | Why? |
| Hemolysis | 1 | 2018 | 283 | 0.15 | Why? |
| Aged | 17 | 2021 | 215776 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.15 | Why? |
| Taste | 1 | 2020 | 715 | 0.15 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2021 | 760 | 0.14 | Why? |
| Meningococcal Infections | 1 | 2018 | 216 | 0.14 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Tertiary Care Centers | 4 | 2021 | 8248 | 0.14 | Why? |
| Adult | 20 | 2021 | 244371 | 0.14 | Why? |
| Chemoprevention | 1 | 2019 | 585 | 0.14 | Why? |
| Immunoglobulin E | 1 | 2017 | 557 | 0.13 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.13 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.13 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.11 | Why? |
| Molecular Targeted Therapy | 1 | 2021 | 1579 | 0.11 | Why? |
| Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.11 | Why? |
| Smell | 1 | 2020 | 1851 | 0.11 | Why? |
| Acute Disease | 2 | 2021 | 6029 | 0.11 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.11 | Why? |
| Infectious Disease Incubation Period | 1 | 2018 | 1033 | 0.10 | Why? |
| Monitoring, Physiologic | 1 | 2021 | 1956 | 0.10 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.10 | Why? |
| Pilot Projects | 2 | 2021 | 5182 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Clostridium Infections | 1 | 2017 | 595 | 0.10 | Why? |
| Pyrimidines | 1 | 2017 | 1557 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.09 | Why? |
| RNA, Ribosomal, 16S | 1 | 2012 | 793 | 0.09 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.09 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.09 | Why? |
| Exanthema | 1 | 2017 | 1097 | 0.08 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.08 | Why? |
| Oxidative Stress | 1 | 2018 | 2050 | 0.08 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.08 | Why? |
| Self Report | 1 | 2019 | 3802 | 0.08 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.08 | Why? |
| Victoria | 2 | 2018 | 607 | 0.08 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.07 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| Receptors, CXCR3 | 1 | 2021 | 159 | 0.05 | Why? |
| Injections, Intravenous | 1 | 2021 | 381 | 0.05 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2021 | 203 | 0.05 | Why? |
| Double-Blind Method | 2 | 2021 | 5988 | 0.05 | Why? |
| Amino Acid Motifs | 1 | 2021 | 620 | 0.05 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.05 | Why? |
| Interleukin-18 | 1 | 2021 | 328 | 0.05 | Why? |
| Rifabutin | 1 | 2017 | 20 | 0.04 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.04 | Why? |
| Cross Infection | 2 | 2018 | 8675 | 0.04 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Antiviral Agents | 2 | 2021 | 41703 | 0.04 | Why? |
| Mycobacterium avium Complex | 1 | 2017 | 61 | 0.04 | Why? |
| Placebos | 1 | 2020 | 629 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2020 | 801 | 0.04 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.04 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.04 | Why? |
| Oxygen | 2 | 2021 | 3715 | 0.04 | Why? |
| Clarithromycin | 1 | 2017 | 112 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 9335 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2020 | 11559 | 0.03 | Why? |
| Th1 Cells | 1 | 2021 | 1228 | 0.03 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2018 | 323 | 0.03 | Why? |
| Adenine | 1 | 2017 | 463 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.03 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.03 | Why? |
| Safety | 1 | 2020 | 1583 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.03 | Why? |
| Feasibility Studies | 1 | 2021 | 3467 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.02 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2021 | 2262 | 0.02 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 877 | 0.02 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Airway Management | 1 | 2018 | 1298 | 0.02 | Why? |
| Animals | 1 | 2017 | 78931 | 0.02 | Why? |
| Seroconversion | 1 | 2017 | 2515 | 0.02 | Why? |
| Vaccination | 1 | 2012 | 19050 | 0.02 | Why? |
| B-Lymphocytes | 1 | 2021 | 4418 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.02 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.02 | Why? |
| Adolescent | 3 | 2019 | 86841 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2019 | 6902 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Child, Preschool | 1 | 2018 | 36283 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.01 | Why? |